Utilization of BioAccord LC-MS System in New Modality
We spoke with multiple universities and pharmaceutical companies about solving challenges related to bio-pharmaceuticals and new modality analysis.
BioAccord LC-MS System 【Antibodies】 Aiming for the enhancement of antibodies as biopharmaceuticals Professor Ito, Department of Life Chemistry, Graduate School of Science and Engineering, Kagoshima University 【MAM】 Increasing MS users for the rapid launch of MAM Astellas Pharma Inc., Pharmaceutical Technology Division, Physical Research Institute 【Nucleic Acids】 For monitoring intermediates in oligonucleotide synthesis Ajinomoto Bio-Pharma Services, Gene Design Inc. Aiming for a wide range of development from small molecules to medium molecules, nucleic acids, and antibodies Shionogi Pharma Co., Ltd. To bring as many nucleic acid medicines as possible to address unmet medical needs Luxana Biotech Inc. Synthesis of functional artificial nucleic acids based on organic chemistry Associate Professor Tarajima and students from the Laboratory of Biological Organic Chemistry, Graduate School of Medical and Dental Sciences, Tokushima University 【Peptides】 For structural estimation of impurities in peptide synthesis Peptide Star Inc.
- 企業：日本ウォーターズ（米国本社 Waters Corporation）
- 価格：Other
